CB2 Insights Agrees To Acquire MedEval Clinic

CB2 Insights, a provider of predictive analytics tools and data-driven software for the cannabis industry, announced plans to expand its business through the acquisition of MedEval Clinic.

What Happened

MedEval, a medical cannabis evaluation and education center group with locations across Colorado and Arizona, represents CB2 Insights' second acquisition since 2017. Previously, the company acquired Massachusetts-based multi-state clinic group Canna Care Docs.

CB2 Insights will pay a combination of cash and stock, although the value and additional terms of the agreement were not disclosed.

The Cannabis Capital Conference is coming back to Toronto! Click here to learn how you can join Tim Seymour, Jon Najarian, Danny Moses, Alan Brochstein and many others.

CB2 Insights went public on the Canadian Securities Exchange at the beginning of March. Prior to the debut, Benzinga sat down with CB2 Insights' CEO Prad Sekar to talk about the company and its plans after it commences trading.

Why This Is Important

The acquisition will allow CB2 Insights to expand its data pool given that MedEval operates two clinics in Colorado and one in Arizona. MedEval represents a medical cannabis evaluation and education center group.

In this way, CB2 will now operate in 14 jurisdictions and plans to increase patient volumes by 10 percent. Prior to the acquisition, CB2 Insights covered around 65,000 patients each year.

In 2018, MedEval had around C$1.0 million ($750,000) in revenue. 

Related Links:

Chicago-Based Grassroots Cannabis Raises $90M To Expand Operations

LeafLink, Canopy Rivers To License B2B Software Platform Internationally